Login to Your Account

Hot on heels of Oralair nod, Merck's Grastek approved for hay fever

By Michael Fitzhugh
Staff Writer

Tuesday, April 15, 2014
Merck & Co. Inc. gained an anticipated FDA approval Monday for Grastek, its immunotherapy tablet for grass pollen-induced allergies, adding direct competition for Greer Laboratories Inc.'s recently approved Oralair.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription